Less Ads, More Data, More Tools Register for FREE

TechMARK movers: Optos grows revenues by 10%

Tue, 18th Jan 2011 12:33
Shares in Optos have fallen back even though there was a 10% year-on-year increase in revenues in the three months to December 2010. The medical retinal imaging company reported a fall in operating lease revenues but these were more than made up for by higher outright sales and sales under finance leases. There were 107 new installations, while the equipment was taken out of 65 sites. Average monthly rental revenues slipped from $2,092 to $2.034 per site. Revenues were $25.7m in the three months to December 2010 and $8m of cash was generated from operations. Opto Global was acquired on 13 December and it did not make a contribution in the quarter. A new product is due to be launched in February. GlaxoSmithKline has fallen further after yesterday's announcement of a £2.2bn legal charge in the fourth quarter of 2010. The majority of the cost relates to product liability cases relating to Avandia (rosiglitazone). The post-tax charge will be £1.8bn. Power components supplier XP Power continues to challenge its highs following last week's positive trading statement. FTSE TechMARK - Risers Renovo Group (RNVO) 75.00p +5.26%Antisoma (ASM) 6.20p +3.16%BAE Systems (BA.) 358.50p +2.60%Promethean World (PRW) 69.75p +2.20%Oxford Biomedica (OXB) 5.60p +2.19%Sepura (SEPU) 49.00p +2.08%Gresham Computing (GHT) 30.00p +1.69%Biocompatibles International (BII) 385.00p +0.79%XP Power Ltd. (DI) (XPP) 1,295.00p +0.78%NCC Group (NCC) 655.00p +0.54%FTSE TechMARK - Fallers ProStrakan Group (PSK) 102.00p -4.67%Sinclair Pharma (SPH) 39.50p -3.07%GlaxoSmithKline (GSK) 1,178.00p -2.24%Renishaw (RSW) 1,296.00p -1.82%Optos (OPTS) 192.50p -1.79%Innovation Group (TIG) 16.25p -1.52%Kewill (KWL) 87.25p -1.41%Vectura Group (VEC) 75.75p -1.30%BATM Advanced Communications Ltd. (BVC) 22.00p -1.12%Vislink (VLK) 23.50p -1.05% Xp Power Glaxosmithkline

Shares in this article

Related News

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
1 day ago

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial

* GSK partner Hansoh reports first late-stage data ​for experimental ⁠lung cancer drug

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
1 day ago

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial

(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or ...

GSK hails 'milestone' drug trial results in China
1 day ago

GSK hails 'milestone' drug trial results in China

(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip c...